Edgewise Therapeutics To Host Webcast Event To Discuss Top-Line Data From Phase 1 Trial In Healthy Subjects And Phase 2 CIRRUS-HCM Trial In Patients With Obstructive HCM On Thursday, September 19 at 8:30 Am ET
Edgewise Therapeutics To Host Webcast Event To Discuss Top-Line Data From Phase 1 Trial In Healthy Subjects And Phase 2 CIRRUS-HCM Trial In Patients With Obstructive HCM On Thursday, September 19 at 8:30 Am ET
Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced that members of the management team will hold a live webcast to discuss top-line data of EDG-7500 from the Phase 1 trial in healthy subjects and the single-dose arm of the Phase 2 CIRRUS-HCMtrial in patients with obstructive HCM on Thursday, September 19, 2024, at 8:30 am ET. The team will be joined by CIRRUS-HCM investigator, Anjali T. Owens, M.D., Medical Director, Center for Inherited Cardiac Disease, Associate Professor of Medicine, University of Pennsylvania, who will share her perspective of EDG-7500 and HCM. An accompanying slide presentation will also be available. To register for the live webcast and replay, please visit the Edgewise events page.
Edgewise Therapeutics, Inc.（納斯達克：EWTX）是一家領先的肌肉疾病生物醫藥公司，今天宣佈管理團隊成員將舉行現場網絡研討會，討論在2024年9月19日週四上午8:30 Et，於健康受試者的EDG-7500一期試驗和患有梗阻性HCm的Phase 2 CIRRUS-HCM試驗的單劑量研究數據。團隊將與CIRRUS-HCm的調查員Anjali T. Owens博士，匹茲堡大學遺傳性心臟病中心主任，匹茲堡大學藥學副教授一起參加，她將分享她對EDG-7500和HCm的看法。附帶幻燈片演示也將提供。要註冊參加現場網絡研討會和回播，請訪問Edgewise事件頁面。
譯文內容由第三人軟體翻譯。